The Humira Biosimilar Market is estimated to be valued at US$ 772.1 million in 2023 and is expected to exhibit a CAGR of 25.9% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.Market Overview:
The Humira Biosimilar market refers to the market for generic versions of Humira, a widely used medication for treating autoimmune diseases such as...
The humira biosimilar market consists of biosimilar versions of the reference biologic drug Humira (adalimumab). Humira is indicated for the treatment of various autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and others. The introduction of biosimilar versions of Humira provides a more cost effective treatment...
The Humira Biosimilar Market is estimated to be valued at US$ 772.1 Million In 2023 and is expected to exhibit a CAGR of 25.9% over the forecast period 2023 - 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview:Humira is a monoclonal antibody used to treat autoimmune diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic...
What are biosimilars?A biosimilar is a biologic medical product that is highly similar to an existing approved branded biologic product, known as the reference product or originator biologic. Biosimilars and their reference products have no clinically meaningful differences in terms of safety, purity, or potency. Biosimilars offer more treatment options and have the potential to reduce...